Stocktoria
Scilex Holding Co SCLX
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-01-11
Scilex Holding Co statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -1143.7% | -147.4% | -225.6% | -133.1% | -114.4% |
| Net margin | -1236.4% | -128.7% | -244.6% | -61.4% | -282.4% |
| FCF margin | 12.2% | 34.2% | -44.4% | 56.0% | -91.5% |
| Return on assets | -102.5% | -78.3% | -112.9% | -27.0% | -113.5% |
| Return on equity | 176.6% | 37.8% | 66.1% | -64.5% | 39.5% |
| Debt / equity | — | — | — | 0.00× | -0.32× |
| Current ratio | 0.08 | 0.16 | 0.19 | 0.66 | 0.14 |
| Revenue growth | -46.5% | 21.1% | 22.9% | 21.4% | 32.9% |
Source: SEC EDGAR filings · CIK 0001820190 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.